Adenium Biotech ApS

Adenium Biotech focuses on the development and commercialization of novel antibiotics for the treatment of Gram-negative bacterial infections (urinary tract infections and hospital- acquired pneumonia). Complicated urinary tract infections are caused predominantly by bacteria Escherichia coli, which is usually easy to cure, however, hospitals-adapted strains are often multi-resistant and can cause life-threatening infections.

Contact name:

Paul Goldenheim


Ole Maaløes Vej 3, 2200 København N, Denmark

If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 5150 0560

Copyright 2011 Danskbiotek. All rights reserved.